Drug Trial Radar · NCT06812780
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389
Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Feb 4, 2025
Primary completion
Sep 4, 2025
Study completion Sep 4, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to examine the safety and tolerability of AZD2389 in participants with hepatic impairment and participants with normal hepatic function.
Conditions
- Hepatic Impairment
Interventions
AZD2389Drug
Single oral dose of AZD2389 in participants from all cohorts
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma PK parameter CmaxTime frame: pre-dose to 48 hours post-dose
- Plasma PK parameter AUCinfTime frame: pre-dose to 48 hours post-dose
- Plasma PK parameter AUClastTime frame: pre-dose to 48 hours post-dose
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Chandler, Arizona
Research Site
Rialto, California
Research Site
Miami Lakes, Florida
Research Site
Orlando, Florida
Research Site
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.